• Completing acquisition in coming weeks -later
Post# of 30066
(Total Views: 426)
Posted On: 12/03/2021 2:19:11 AM
.jpg)
• Completing acquisition in coming weeks -later December. Brings Dorit Arad under Todos via 3CL.
• Expect some high need jurisdictions may allow EUA. Sooner than expected.
• Expect P2b/3 with interim and final data for those needing more data
• Building up supply chain to meet potential demand. Looking at volume for worldwide service.
• Pre-IND meeting with FDA postponed until data in coming weeks
• Strategic partnerships being evaluated in different regions
• Hastening development of chemical entities to enable scale of doses for pandemic. Enhances value of program to BP partners.
• Working on second “much larger” Tollovid purchase order
• Working on other Tollovid distribution agreements in other regions
• May move away from 3rd party manufacturing
• Videssa Test will complete full launch in 2022. Study begin Q122, to complete 2H 2022. Launch early 2023.
• Currently enrolling 2nd cohort of 40 person Lympro Study in Leipzig. Data expected 1H 2022.
• Expecting continued pipeline of Alzheimers drugs to attach screening test to
• Most noteholders have agreed to convert to preferred shares upon uplist
• Investment Bank engaged to lead underwriting
• Application to uplist in coming weeks
• Uplist Q1/22
• Improving collection of reimbursements in timely manner. Major positive impact on cash flow
• Tollovir Data could drastically alter or eliminate ratio for R/S
• Because Todos was never a shell company, Todos does not have to wait 30 days to uplist.
• Headwinds to testing that requires transport over holiday heavy shipping season
• Believe media will pick up story with Data
• Expect some high need jurisdictions may allow EUA. Sooner than expected.
• Expect P2b/3 with interim and final data for those needing more data
• Building up supply chain to meet potential demand. Looking at volume for worldwide service.
• Pre-IND meeting with FDA postponed until data in coming weeks
• Strategic partnerships being evaluated in different regions
• Hastening development of chemical entities to enable scale of doses for pandemic. Enhances value of program to BP partners.
• Working on second “much larger” Tollovid purchase order
• Working on other Tollovid distribution agreements in other regions
• May move away from 3rd party manufacturing
• Videssa Test will complete full launch in 2022. Study begin Q122, to complete 2H 2022. Launch early 2023.
• Currently enrolling 2nd cohort of 40 person Lympro Study in Leipzig. Data expected 1H 2022.
• Expecting continued pipeline of Alzheimers drugs to attach screening test to
• Most noteholders have agreed to convert to preferred shares upon uplist
• Investment Bank engaged to lead underwriting
• Application to uplist in coming weeks
• Uplist Q1/22
• Improving collection of reimbursements in timely manner. Major positive impact on cash flow
• Tollovir Data could drastically alter or eliminate ratio for R/S
• Because Todos was never a shell company, Todos does not have to wait 30 days to uplist.
• Headwinds to testing that requires transport over holiday heavy shipping season
• Believe media will pick up story with Data
(3)
(0)